Investment Rating - The industry investment rating is maintained at "Overweight" [3] Core Insights - The retail sector experienced a significant increase of 6.66% last week, outperforming the CSI 300 index by 6.94 percentage points [5][10] - The current Price-to-Earnings (PE) ratio for the retail sector is 52X, which is a 3.25 percentage point increase from the previous week, with a one-year range of 31.27X to 52X [6][17] - The launch of the Hainan Free Trade Port and the implementation of a new customs supervision system are expected to create new growth opportunities for the retail sector, particularly through the expansion of the "zero tariff" product catalog [7][21][22] Summary by Sections Industry Performance - The retail sector's index closed at 2458.79 points, with a weekly increase of 6.66%, ranking first among the Shenwan primary industries [5][10] - Various sub-sectors showed positive performance, with general retail up 9.67% and professional chains up 5.06% [11] Industry Dynamics - The Hainan Free Trade Port's full closure has been officially launched, allowing for maximum freedom of goods movement between Hainan and overseas, while maintaining efficient regulation with the mainland [7][21] - The "zero tariff" policy has expanded significantly, increasing the number of duty-free items from approximately 1,900 to about 6,600, enhancing the competitiveness of retail prices in Hainan [22][24] Investment Recommendations - Focus on leading duty-free retailers that hold duty-free operating licenses, as they are the most direct beneficiaries of the new policies [8][25] - High-end consumer goods and department stores are expected to benefit from the favorable retail environment created by the closure [8][25] - Modern logistics and supply chain service providers will see increased business volume due to the expected growth in people and goods movement [8][25] Valuation Metrics - The current Price-to-Book (PB) ratio for the retail sector is 2.09X, with a one-year range of 1.52X to 2.1X [6][18]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][9] Core Insights - The medical services sector has shown resilience, with a slight increase in valuation despite overall market corrections, highlighting its value proposition [6][9] - The recent passage of the U.S. 2026 National Defense Authorization Act (NDAA) is expected to ease the immediate impact on the domestic biopharmaceutical industry, particularly for companies like WuXi AppTec and WuXi Biologics [5][61] Summary by Sections Industry Performance - The pharmaceutical and biological sector declined by 0.14%, ranking 22nd among 31 primary industries [1][11] - The medical services sub-sector index closed at 6344.37 points, up by 0.55% [22][23] Company Performance - Top-performing companies in the medical services sector include: - Meinian Health (+24.1%) - Baihua Pharmaceutical (+8.8%) - Dian Diagnostics (+8.1%) [2][27] - Underperforming companies include: - Nanhua Biological (-6.5%) - Medisyn (-5.2%) [2][27] Valuation Metrics - The current Price-to-Earnings (PE) ratio for the medical services sector is 32.03X, with a Price-to-Book (PB) ratio of 3.23X [3][29] - The PE ratio has increased by 0.29X from the previous week, while the PB ratio has risen by 0.03X [29] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the peptide CDMO in the weight-loss drug supply chain, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [9][62] - It also recommends monitoring third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, with companies like Aier Eye Hospital and Dian Diagnostics [9][62]

Investment Rating - The industry rating is maintained at "Overweight" [6][8][35] Core Insights - The "New Year Opening" strategy of small and medium-sized banks is characterized by high interest rates on deposits, which is expected to support steady credit issuance [6][30] - Large banks are experiencing a significant increase in deposit growth, attributed to regulatory changes and their strong wealth management capabilities, which allow them to attract deposits effectively [6][31] - The competitive landscape indicates that small and medium-sized banks must leverage their local advantages and focus on serving small and micro enterprises to differentiate themselves from larger banks [7][33] Summary by Sections Industry Performance - Deposits are shifting from small and medium-sized banks to large banks, with large banks showing a notable increase in deposit growth since the first quarter of this year [6][31] - The increase in deposit rates by small and medium-sized banks aims to attract savings and counteract structural changes in the deposit market [30][31] Future Outlook - Large banks are expected to continue expanding their market share in the small and micro finance sector, supported by government policies aimed at reducing costs and improving efficiency [7][33] - The "New Year Opening" period is anticipated to see steady growth in credit issuance from large banks, bolstered by favorable fiscal policies [8][35] Investment Recommendations - It is advised to focus on state-owned banks with stable asset deployment and regional banks with growth potential under economic recovery expectations, including recommendations for specific banks such as Industrial and Commercial Bank of China, Bank of China, and others [8][35]

Investment Rating - The industry investment rating is maintained at "Overweight" [2][5] Core Insights - The medical consumables sector saw a weekly increase of 2.29%, outperforming the CSI 300 index by 0.14 percentage points [2][4] - The current PE (ttm) for the medical consumables sector is 35.38X, with a PB (lf) of 2.54X, indicating a slight increase in valuation metrics compared to the previous week [3][16] - Recent policy changes from the National Health Commission aim to enhance the capabilities of grassroots medical institutions, which is expected to drive demand for specialized medical equipment and consumables [4][19] - The initiation of centralized procurement for high-frequency electric knives across 29 provinces presents opportunities for domestic brands to gain market share [4][20][22] Summary by Sections Industry Performance - The medical consumables sector reported a weekly increase of 2.29%, with a current index value of 5840.56 points [2][8] - The sector's performance over the past 12 months shows a relative decline of 9% compared to the CSI 300 index [2] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 35.38X, with a year-to-date maximum of 40.1X and a minimum of 28.88X [3][16] - The PB ratio stands at 2.54X, with a maximum of 2.92X and a minimum of 2.13X over the past year [3][18] Industry Dynamics and Announcements - The National Health Commission's new guidelines encourage grassroots medical institutions to upgrade from general to specialized departments, increasing the demand for specific medical consumables [4][19] - The centralized procurement initiative for high-frequency electric knives is expected to facilitate domestic brands' entry into mainstream hospitals, with a pricing mechanism that rewards product differentiation [4][20][22] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly those benefiting from domestic substitution and policy guidance in the rehabilitation and chronic disease management sectors [5][24] - Specific companies to watch include those with diverse product lines and high innovation in high-value consumables, such as electrophysiology and interventional products [5][24]

Investment Rating - The industry rating is maintained at "Overweight" [3][10] Core Insights - The rare earth magnetic materials industry has underperformed the market, with a decline of 1.81% this week, lagging behind the benchmark (CSI 300) by 1.53 percentage points [5][12] - The industry valuation (TTM P/E) has decreased by 1.42x to 72.08x, currently at the 85.5% historical percentile [5][12] - Supply of rare earths remains tight, with separation companies continuing to reduce production, and no new output expected [40] - Demand from downstream sectors is stable but weak, with a decrease in procurement intentions due to high upstream prices [40] Summary by Sections Industry Performance - Over the past month, the industry has shown a relative return of -1%, -6% over three months, and a significant 53% over twelve months [4] - Absolute returns are -2% for one month, -4% for three months, and 69% for twelve months [4] Price Trends - Prices for imported light and medium-heavy rare earth ores continue to decline, with specific decreases noted in praseodymium-neodymium and dysprosium prices [6][9][20] - The average price of praseodymium-neodymium oxide has decreased by 0.86% to 574,000 CNY/ton, while the metal price has dropped by 1.06% to 697,500 CNY/ton [14][16] - Dysprosium and terbium prices have also continued to fall, with dysprosium oxide down 1.46% and terbium oxide down 2.23% [20] Investment Recommendations - The report suggests maintaining an "Overweight" rating, highlighting that while there is pressure on high valuations due to low risk appetite, the market may stabilize with improved downstream operations and export demand [10][41] - It is recommended to focus on upstream rare earth resource companies due to expected supply tightening and strategic value positioning, as well as on downstream magnetic material companies with strong customer structures and growth potential [10][43]

证券研究报告 2025 年 11 月 21 日 湘财证券研究所 金融工程研究 策略双周报 期权波动率套利策略跟踪 ——波动率偏斜策略 相关研究： 核心要点： ❑ 波动率偏斜策略跟踪情况 波动率偏斜策略是通过价内合约与价外合约的隐含波动率差异进行套利交 易。正常情况下，VSI 指标会在一定范围内波动，但当不同期权合约的波 动率比值出现实质差异时，就存在相应的反向套利空间。 本年以来，认购子策略收益率为 8.49%，最大回撤为 2.93%；认沽子策略 收益率为-1.31%，最大回撤为 10.49%；组合策略收益率为 3.68%，最大回 撤为 5.57%。 近两周以来（2025 年 12 月 8 日至 2025 年 12 月 19 日），认购子策略的收 益率为 0.91%，最大回撤为 0.09%；认沽子策略收益率为 0.46%，最大回撤 为 0.29%；组合策略收益率为 0.68%，最大回撤为 0.13%。 ❑ 投资建议 近两周以来，标的资产以震荡走势为主，从 VSI 指标偏离情况来看，认购 合约和认沽合约都出现了轻微偏离但很快回归的现象，套利策略非常适用 于这类市场走势，从策略收益来看，认购和认沽子策略均获得了正 ...

证券研究报告 2025 年 12 月 21 日 湘财证券研究所 行业研究 证券行业周报 板块安全边际较高，关注左侧布局机会 1.《行业周报：市场交投保持活跃， 关 注 券 商 估 值 修 复 机 会 》 2025.12.21 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -1 -3 -16 绝对收益 -1 -1 0 -30% -20% -10% 0% 10% 20% 30% 2024/12/19 2025/2/19 2025/4/19 2025/6/19 2025/8/19 2025/10/19 2025/12/19 沪深300 证券Ⅱ(申万) 相关研究： 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： ❑ 市场回顾：本周非银和券商指数领涨，估值仍处于低位 根据 Wind 数据，本周（12.15-12.19）上证指数上涨 0.03%，沪深 300 指数 下跌 0.3%，创 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2][9] Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [9][28] - Recent clinical trial approvals for innovative vaccines by companies like Zhifei Biological, Kangtai Biological, Wantai Biological, and CanSino indicate significant advancements in the field, particularly in addressing emerging infectious diseases and specific patient populations [4][8] Summary by Sections Industry Performance - The vaccine sector has seen a relative decline, with a 12-month absolute return of -14% and a relative return of -28% compared to the CSI 300 index [4][5] - The vaccine index closed at 11,363.86, down 0.87% last week, while the overall pharmaceutical sector saw a slight decline of 0.14% [5][11] Market Review - The vaccine sector's performance has been lagging, with a cumulative decline of 10.1% since the beginning of 2025, indicating a challenging market environment [5][11] - Notable companies in the vaccine sector include Liaoning Chengda, Hualan Biological, and Kangtai Biological, which have shown better performance compared to others like Kanghua Biological and CanSino [6][11] Valuation - The vaccine sector's price-to-earnings (PE) ratio is 92.32X, reflecting a decrease of 0.74X week-on-week, while the price-to-book (PB) ratio stands at 1.79X, also showing a slight decline [7][11] - The PE ratio is at the 56.20% percentile since 2013, while the PB ratio is at the 1.36% percentile, indicating a relatively high valuation compared to historical data [7][11] Investment Recommendations - The vaccine industry is under pressure, with companies focusing on pipeline adjustments and innovation to enhance competitiveness. Long-term prospects hinge on innovation and international expansion [8][9] - Companies with strong research and development capabilities and differentiated product offerings, such as CanSino and Kanghua Biological, are recommended for investment [9][28]

Core Insights - The report indicates that the A-share indices experienced a downward trend during the week of December 15-19, 2025, with most indices showing fluctuations [2][11][14] - The decline in A-share indices is attributed to weak macroeconomic data related to investment and consumption, as well as external factors such as the Federal Reserve's interest rate decisions [4][14] - The report anticipates that 2026 will be a pivotal year for China's economic development, with supportive policies expected to foster a favorable environment for industrial upgrades and a "slow bull" market [4][9] Economic Data Summary - Fixed asset investment in China showed a cumulative year-on-year decline of 2.60% for the first eleven months of 2025, marking three consecutive months of negative growth [7][27] - Infrastructure investment has decreased significantly from a high of 11.50% in March 2025 to just 0.13% by November 2025, while manufacturing investment also fell from 9.10% to 1.90% in the same period [7][27] - Real estate development investment has consistently been negative, with a cumulative decline of 15.90% for the first eleven months of 2025 [7][27] Industry Performance Summary - Among the 31 first-level industries, the retail and non-bank financial sectors showed the highest weekly gains of 6.66% and 2.90%, respectively, while the electronics and power equipment sectors faced declines of -3.28% and -3.12% [5][21] - In the second-level industry categories, aerospace equipment II and general retail led with weekly increases of 14.33% and 9.67%, while the film and television sector and other electronics II saw declines of -5.68% and -4.63% [5][24] - The third-level industries saw aerospace equipment III and supermarkets with the highest weekly gains of 14.33% and 14.18%, while the film and animation production sector and photovoltaic processing equipment faced the largest declines of -6.84% and -6.37% [6][26] Investment Recommendations - The report suggests a long-term positive outlook for 2026, emphasizing the importance of supportive policies for industrial upgrades and the entry of long-term capital into the market [9][32] - In the short term, it is recommended to focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas supported by policy [9][32]

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - The demand for AI computing power is driving both the quantity and price of PCBs upward, with significant growth expected in the AI PCB market [8] - The introduction of the Rubin architecture is anticipated to enhance the value of PCBs in servers, with the value of a single server's PCB expected to more than double compared to previous generations [4] - The upgrade of data center switches is also contributing to the increase in PCB value, as the number of PCB layers and material quality are improving [5] - AI server and high-speed switch demand is projected to grow rapidly, driven by substantial capital expenditures from major AI and internet companies [6][8] Summary by Sections Industry Performance - Over the past 12 months, the electronic industry has shown a relative return of 21.9% compared to the CSI 300 index, with an absolute return of 37.7% [3] Investment Recommendations - The report highlights a sustained recovery in consumer electronics, with new foldable smartphones being released and advancements in AI technology driving high demand for AI infrastructure [7][15] - The report emphasizes that the capital expenditure growth in data centers will lead to a compound annual growth rate of 21% by 2029, further supporting the expansion of computing power clusters [6][8]